Multicenter, Randomized, Non-comparative, Controlled Study of Therapeutic Intensification Plus Immunomodulation in HIV-infected Patients With Long-term Viral Suppression
Latest Information Update: 11 May 2022
At a glance
- Drugs HIV DNA vaccine (Primary) ; Maraviroc (Primary) ; Raltegravir (Primary) ; V 520 (Primary)
 - Indications HIV-1 infections
 - Focus Therapeutic Use
 - Acronyms EraMune-02
 
Most Recent Events
- 11 Sep 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
 - 30 Jan 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
 - 13 Jun 2011 Planned end date changed from 1 Jul 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.